Babesiosis is an emerging tick-borne disease caused by intraerythrocytic Babesia protozoa (primarily B. microti in the US), transmitted by Ixodes scapularis ticks, blood transfusion, organ transplantation, or perinatally. [1-2] It is endemic to the northeastern and upper midwestern United States, with incidence sharply increasing in recent years, particularly in New England. [3-4] The clinical spectrum ranges from asymptomatic infection (~25% of adults) to severe, life-threatening hemolytic disease. [2][5]
1. History
- Tick exposure: Recent outdoor activity in endemic area (Northeast/Upper Midwest US), time of year (peak May–September), known tick bite (most patients do not recall the bite) [6]
- Onset: Gradual onset of malaise, anorexia, fatigue, followed days later by fever, drenching sweats, myalgia, headache [2][6]
- Timing: Symptoms typically begin ~1–4 weeks after tick bite; transfusion-transmitted cases may present 1–9 weeks (up to 6 months) after transfusion [1]
- Symptom characterization: Intermittent high fevers, rigors, drenching night sweats, dark urine (hemoglobinuria) [2]
- Associated symptoms: Arthralgia, anorexia, nausea, abdominal pain, dry cough, sore throat, photophobia [2]
- Important negatives: No erythema migrans rash (unlike Lyme), no eschar; ask about concurrent Lyme symptoms (~20% coinfection rate in endemic areas) [1][6]
2. Alarm Features
- Parasitemia ≥10% — threshold for considering exchange transfusion [1][3]
- Hemodynamic instability / shock [1-2]
- Acute respiratory distress syndrome (ARDS) [1][5]
- Severe hemolytic anemia (Hgb <7 g/dL with elevated LDH) [3]
- Acute kidney injury, liver failure [1]
- Disseminated intravascular coagulation (DIC) [1-2]
- Altered mental status / coma [2][5]
- Splenic infarct or rupture — may occur even with low parasitemia [7]
- Congestive heart failure [1][5]
3. Medications
- Preferred (mild-moderate): Atovaquone 750 mg PO Q12h (with fatty meal) + azithromycin 500 mg PO day 1, then 250 mg daily × 7–10 days [1]
- Alternative: Clindamycin 600 mg PO Q8h + quinine sulfate 650 mg PO Q8h × 7–10 days (more side effects) [1][7]
- Severe/hospitalized: Atovaquone 750 mg PO Q12h + azithromycin 500 mg IV Q24h; alternative is clindamycin 600 mg IV Q6h + quinine sulfate 650 mg PO Q8h [1]
- Immunocompromised: Treat ≥6 weeks, including 2 weeks after blood smear clearance; consider higher-dose azithromycin (500–1000 mg/day) [1][7]
- Quinine cautions: Frequent adverse effects (tinnitus, GI upset, cinchonism); quinidine (if used IV) requires cardiac monitoring for QT prolongation — quinidine is no longer available in the US [1][5]
- Coinfection consideration: Add doxycycline empirically if Lyme disease or anaplasmosis coinfection is suspected [7-8]
4. Diet
- Atovaquone must be taken with a fatty meal to ensure adequate absorption [1]
- Maintain adequate hydration, especially with hemolysis and hemoglobinuria
- No specific dietary triggers or restrictions beyond medication-related considerations
5. Review of Systems
- Constitutional: Fever pattern, chills, rigors, night sweats, fatigue, weight loss
- HEENT: Headache, photophobia, conjunctival injection, sore throat, scleral icterus [2]
- Pulmonary: Dyspnea, cough (screen for ARDS)
- GI: Nausea, vomiting, anorexia, abdominal pain (splenic pathology)
- GU: Dark urine (hemoglobinuria), decreased urine output (AKI)
- MSK: Myalgia, arthralgia
- Neuro: Altered mental status (severe disease)
- Heme: Easy bruising, petechiae (thrombocytopenia/DIC)
6. Collateral History and Family History
- Travel history: Residence in or travel to endemic areas within the past month [1]
- Blood transfusion history: Within the past 6 months — transfusion-transmitted babesiosis carries ~20% fatality rate [1]
- Organ transplant history: Donor-derived transmission is possible [2]
- Immunosuppressive medications: Rituximab, anti-TNF agents, transplant immunosuppression [5]
- Splenectomy history: Critical risk factor for severe disease [2][5]
- Family history is generally not contributory (not a hereditary condition)
7. Risk Factors
- Asplenia / prior splenectomy — strongest risk factor for severe disease [2][5]
- Age >50 years (median age of severe cases ~71 years) [2-3]
- Immunosuppression: B-cell lymphoma, rituximab therapy, HIV with low CD4, solid organ/stem cell transplant, anti-cytokine therapy (etanercept, infliximab) [5][7]
- Cardiac or renal comorbidities — associated with babesiosis-related sepsis [9]
- Hemoglobinopathies [5]
- Chronic heart, lung, or liver disease [5]
- Blood transfusion recipients in endemic areas [1]
- Outdoor activities in endemic regions during tick season [4]
8. Differential Diagnosis
- Malaria — most important mimic; ring forms on smear can be confused with P. falciparum; distinguish by absence of pigment deposits, schizonts, and gametocytes in babesiosis; Maltese cross is pathognomonic for Babesia [1][6]
- Anaplasmosis (HGA) — coinfection common; look for morulae in neutrophils, leukopenia more prominent [8]
- Lyme disease — ~20% coinfection rate; erythema migrans rash distinguishes; consider if fever persists >48h on Lyme therapy [6-7]
- Ehrlichiosis — similar nonspecific febrile illness; morulae in monocytes
- Viral syndromes (EBV, CMV, influenza) — lack hemolytic anemia and parasitemia
- Autoimmune hemolytic anemia — DAT positive; no parasites on smear
- Thrombotic thrombocytopenic purpura (TTP) — schistocytes, ADAMTS13 activity low
- Hemolytic uremic syndrome (HUS) — renal failure, schistocytes, diarrheal prodrome
- Sepsis from other causes — blood cultures, broader workup
9. Past Medical History
- Prior splenectomy or functional asplenia
- History of tick-borne diseases (prior Lyme, anaplasmosis)
- Malignancy, especially B-cell lymphoma
- HIV status and CD4 count
- Organ transplant status and immunosuppressive regimen
- Chronic cardiac, pulmonary, hepatic, or renal disease
- Prior blood transfusions
- Previous episodes of babesiosis (relapse risk in immunocompromised) [1][7]
10. Physical Exam
- Vital signs: Fever (often high, intermittent), tachycardia, hypotension (severe cases)
- General: Ill-appearing, diaphoretic
- HEENT: Scleral icterus, conjunctival pallor, conjunctival injection [2]
- Abdomen: Mild splenomegaly, mild hepatomegaly, tenderness (splenic infarct/rupture) [2]
- Skin: Jaundice; no characteristic rash (unlike Lyme); check for embedded ticks or tick bite site
- Pulmonary: Crackles (ARDS in severe cases)
- Neuro: Altered mental status (severe/late disease)
- Petechiae/ecchymoses: If DIC or severe thrombocytopenia
11. Lab Studies
- Peripheral blood smear (Giemsa or Wright stain) — first-line diagnostic test; look for intraerythrocytic ring forms and pathognomonic Maltese cross (tetrad) configuration [1][7]
- Babesia PCR — more sensitive than smear, especially with low parasitemia; recommended if smear negative but clinical suspicion remains [1]
- Parasitemia quantification — critical for severity assessment and exchange transfusion decision [1]
- CBC: Hemolytic anemia, thrombocytopenia (very common), leukopenia or normal WBC [6]
- Hemolysis labs: Elevated LDH, elevated indirect bilirubin, low haptoglobin, elevated reticulocyte count [6]
- BMP/CMP: Creatinine (AKI), hepatic transaminases (elevated in ~50%) [6]
- Urinalysis: Hemoglobinuria
- Coagulation studies: PT/INR, fibrinogen, D-dimer (if DIC suspected)
- DAT (Coombs test): May be positive (warm autoimmune hemolytic anemia can complicate babesiosis) [1]
- Babesia serology (IFA): IgM ≥1:16 and IgG ≥1:1024 suggest acute infection; not recommended for acute diagnosis alone — cannot distinguish active from prior infection [1][10]
- Co-infection testing: Lyme serology, Anaplasma PCR/smear in endemic areas [1][10]
12. Imaging
- No specific imaging is required for diagnosis of babesiosis
- Chest X-ray: If dyspnea or hypoxia — evaluate for ARDS, pulmonary edema
- CT abdomen: If abdominal pain — evaluate for splenic infarct or rupture (may occur even with low parasitemia) [7]
- Echocardiography: If signs of heart failure in severe disease
- Imaging is otherwise guided by clinical complications, not routine
13. Special Tests
- Peripheral blood smear — gold standard for rapid diagnosis; request manual (non-automated) review explicitly [2]
- Maltese cross (tetrad) formation — pathognomonic but infrequently observed [1]
- Babesia PCR (real-time or 18S rRNA RT-PCR) — more sensitive than smear; useful for low-grade parasitemia and species identification [1]
- Parasitemia percentage — essential for treatment stratification and exchange transfusion decisions
- SOFA score — used to define acute organ injury in severe babesiosis [3]
- Pan-Babesia PCR — if non-B. microti species suspected (e.g., B. duncani, B. divergens) [1]
14. ECG
- Indicated if: Using quinine (monitor for QT prolongation, cinchonism) or quinidine (continuous cardiac monitoring required) [5]
- Severe disease: Evaluate for arrhythmias, myocardial dysfunction
- Findings to watch for: QT prolongation (quinine/quinidine), tachycardia, signs of hyperkalemia (if AKI/hemolysis)
15. Assessment
Severity stratification per IDSA guidelines: [1]
- Mild-moderate: Immunocompetent, parasitemia <4%, mild symptoms, no organ dysfunction → outpatient management
- Severe: Parasitemia ≥5–10% with organ injury or severe hemolytic anemia, or parasitemia >10% → hospitalization required
- Life-threatening: Parasitemia >10% with ARDS, DIC, shock, renal failure, hepatic failure, or altered mental status → ICU, consider exchange transfusion
Approximately half of hospitalized patients develop one or more complications. [1] Mortality among hospitalized patients ranges from 2.8–8.8%, reaching up to 20% in immunocompromised patients and transfusion-transmitted cases. [1][3] Coinfection with Lyme disease and/or anaplasmosis should always be considered in endemic areas. [1]
16. Treatment Plan
Mild-moderate (outpatient)
- Atovaquone 750 mg PO Q12h (with fatty meal) + azithromycin 500 mg PO day 1, then 250 mg PO daily × 7–10 days [1]
- Alternative: Clindamycin 600 mg PO Q8h + quinine sulfate 650 mg PO Q8h × 7–10 days [1]
Severe (inpatient)
- Atovaquone 750 mg PO Q12h + azithromycin 500 mg IV Q24h until symptoms improve, then step down to oral [1]
- Alternative: Clindamycin 600 mg IV Q6h + quinine sulfate 650 mg PO Q8h [1]
- Total course: 7–10 days for immunocompetent patients
Exchange transfusion (ET) — consider for: [1][3][7]
- Parasitemia >10%, OR
- Parasitemia 5–10% with acute organ injury or severe hemolytic anemia (Hgb <7 g/dL + LDH >3× ULN)
- Target: ≥90% reduction in parasitemia; exchange ~2.5× patient RBC volume
- The STOP-BABESIOSIS study (2026) demonstrated that ET was associated with a nearly 5-fold lower adjusted risk of in-hospital death or 30-day readmission (3.6% vs 9.8%; aOR 0.22) [3]
Highly immunocompromised patients
- Treat for ≥6 weeks, including 2 final weeks with negative blood smears [1][7]
- Consider azithromycin 500–1000 mg/day [1]
- Reduce immunosuppression when possible [1]
17. Disposition
- Discharge criteria: Immunocompetent, mild-moderate symptoms, parasitemia <4%, no organ dysfunction, able to tolerate oral medications, reliable follow-up [1]
- Admission criteria: Parasitemia ≥4%, hemodynamic instability, significant hemolytic anemia, organ dysfunction, immunocompromised host, inability to tolerate oral medications [1]
- ICU admission: Shock, ARDS, DIC, parasitemia >10%, need for exchange transfusion
- Specialist consultation triggers: [2]
- Infectious diseases — all severe or immunocompromised cases
- Hematology/transfusion medicine — if exchange transfusion considered
- Age extremes (neonates, >50 years) or at-risk populations
18. Follow Up / Return Precautions
- Immunocompetent patients: Symptoms typically improve within days of starting treatment; fever and parasitemia usually clear within 1 week. Fatigue may persist for weeks to months and alone is not an indication for retreatment [1]
- Follow-up blood smear: Repeat to confirm parasitemia clearance; PCR may remain positive for months after successful treatment and does not indicate treatment failure in immunocompetent patients [1]
- Immunocompromised patients: Monitor with serial blood smears every 2 weeks until negative for ≥2 consecutive weeks before stopping therapy [1][7]
- Return precautions: Instruct patients to return for worsening fever, dark urine, jaundice, dyspnea, abdominal pain (splenic complications), confusion, or signs of bleeding
- Tick prevention counseling: DEET-based repellents, permethrin-treated clothing, daily tick checks, prompt tick removal [4]
- Reportable disease: Babesiosis is nationally notifiable in the US [4]
References
1. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. — Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021.
2. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
3. Red Blood Cell Exchange Transfusion for Severe Babesiosis. — STOP-BABESIOSIS Investigators, Leaf DE, Monson AE, et al. JAMA Internal Medicine. 2026.
4. Trends in Reported Babesiosis Cases - United States, 2011-2019. — Swanson M, Pickrel A, Williamson J, Montgomery S. MMWR. Morbidity and Mortality Weekly Report. 2023.
5. Human Babesiosis. — Vannier E, Krause PJ. The New England Journal of Medicine. 2012.
6. Tick-Borne Diseases in the United States. — Spach DH, Liles WC, Campbell GL, et al. The New England Journal of Medicine. 1993.
7. Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review. — Sanchez E, Vannier E, Wormser GP, Hu LT. The Journal of the American Medical Association. 2016.
8. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. — Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021.
9. Babesiosis-Related Sepsis: Clinical Characteristics and Outcomes From a Multicenter Retrospective Global Research Network Analysis. — Long J, Henao-Martínez AF, Rau N, Vorkas CK, Marcos LA. The American Journal of Tropical Medicine and Hygiene. 2026.
10. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.